Threolone

Quick links to important sections

Threolone

Method of action: Ophthalmologicals

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Threolone

Property Description
Active ingredient Chloramphenicol, Prednisolone Acetate
Form Topical Ointment
Pharmacological Class Broad-spectrum antibiotic and Glucocorticoid (Corticosteroid) Combination
General Purpose To address both bacterial growth and associated inflammation in dermatoses
Origin Synthetic

What Type of Medicine is Threolone? (Definition and Classification)

Threolone is defined as a synthetic fixed-dose combination product administered via the Topical Route, primarily formulated as an Ointment. Its pharmaceutical classification places it as a combination of a Broad-spectrum antibiotic and a potent Glucocorticoid or Corticosteroid. This dual-component designation allows it to address complex localized skin issues requiring both anti-infective and anti-inflammatory activity. The Topical Ointment form is clinically recognized for its localized action, minimizing systemic exposure while providing high concentration directly to the affected skin area.


Composition: The Dual Active Ingredients

The essential identity of Threolone is its two Active ingredients: Chloramphenicol and Prednisolone Acetate. Chloramphenicol functions as the Anti-infective/Antibacterial component, while Prednisolone Acetate provides the necessary Anti-inflammatory/Glucocorticoid component. Chloramphenicol is noted for its Bacteriostatic effect, meaning it stops bacteria from multiplying. Prednisolone Acetate, a synthetic steroid, is distinguished by its high lipophilicity, which enhances its penetration through the skin layers in the ointment base. This fixed-dose formulation targets specific skin lesions, such as Angular stomatitis or infected eczema, which require simultaneous antibacterial action and reduction of severe inflammation.


General Purpose and Action of the Combination

The general purpose of Threolone is to deliver a synergistic effect to the affected skin area. The combined actions aim to reduce the signs and symptoms of Skin infections or complicated Dermatoses where inflammation is a key feature. The Antibacterial action of Chloramphenicol targets the bacterial growth, and the Anti-inflammatory effect of Prednisolone Acetate rapidly alleviates discomforting symptoms like swelling, redness, and itching. This dual-action approach is well-established in dermatological practice for conditions that have evolved past simple inflammation, requiring the added benefit of infection control.

Regulatory References

  1. StatPearls: Prednisolone

What side effects are possible with Threolone?

Possible Side Effects and Safety Information

The official safety profile for Threolone, a combination of Chloramphenicol and Prednisolone Acetate, is categorized by two distinct sets of risks based on its active components. Adverse reactions are formally classified by frequency and system-organ class, following standards established in regulatory documents.


Key Adverse Reaction Classifications

Frequency Classification Examples of Officially Documented Adverse Reactions
Common / Expected Transient burning, stinging, or local irritation at the site of application.
Rare / Very Rare (but Serious) Aplastic anemia or bone marrow suppression (associated with Chloramphenicol); HPA axis suppression, Cushing's syndrome, glaucoma, or cataracts (associated with the corticosteroid component).

Systemic and Duration-Related Safety Patterns

Side effects typically involve the Skin and Subcutaneous Tissue Disorders (e.g., skin atrophy, striae) and may involve Endocrine Disorders (HPA axis suppression) or Eye Disorders (increased intraocular pressure) upon systemic absorption or prolonged use. These serious effects, including glaucoma and cataract formation, are specifically associated with prolonged or long-term application of the corticosteroid component.

Regulatory documents highlight special safety considerations for certain groups. Pediatric patients are identified as more susceptible to systemic toxicity from corticosteroid absorption, including the risk of growth retardation, due to physiological differences. Furthermore, official labeling generally contraindicates the use of this combination in the presence of specific existing infections, such as viral or fungal diseases, as the steroid component may potentially worsen these underlying conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for this product addresses the potential for systemic toxicity resulting from the over-application, prolonged use, or accidental ingestion of its two active components.

Documented Overdose Presentations

Toxicity Component Signs and Symptoms Documented in Regulatory Sources
Chloramphenicol Toxicity Acute systemic overdose may present with hypotension, hypothermia, nausea, vomiting, and abdominal distension [Source 1.3].
Corticosteroid Overuse Chronic over-application can lead to signs of HPA axis suppression, Cushing's syndrome manifestations, hyperglycemia, and glucosuria [Source 3.3, 3.5].

Serious Outcomes and Actions Required

Excessive systemic exposure carries a low but serious risk of outcomes, including fatal aplastic anaemia and cardiovascular collapse [Source 1.3, 1.6].

  • Emergency Action: Regulatory guidance mandates that you seek immediate medical attention or consult a Poison Center right away if the product is ingested or if a significantly higher dose than recommended is used [Source 2.1].
  • Monitoring and Withdrawal: If HPA axis suppression is documented (a risk with use over large areas or under occlusion), the corticosteroid component is required to be gradually withdrawn [Source 3.3].
  • Population Note: Pediatric patients are at greater risk for systemic effects, and Gray baby syndrome is a documented, severe toxicity in infants exposed to Chloramphenicol [Source 1.3, 3.5]. No specific antidote is known for overdose of either component.

Therapeutic Uses of Threolone

What Threolone Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed in situations involving a bacterial presence, primarily in the eye, ear, and skin.

This medication is commonly used across conditions presenting with acute or disruptive episodes, relevant in contexts involving inflammatory or irritative processes affecting the eye, ear, and skin, where a bacterial presence is a factor. The steroid component supports management of inflammation in certain infective conditions, which is considered relevant for this dual approach.

The therapy helps address symptom clusters related to inflammatory or irritative states, which may include pronounced discomfort, swelling, and redness. “This medication is relevant in clinical settings that involve acute or unstable symptom patterns where localized symptoms create noticeable physiological strain.” This is commonly used when symptoms intensify and supportive relief is needed, contributing to improved comfort and assisting with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Acute Inflammation and Pain

Regulatory References

  1. DailyMed NLM overview on Prednisolone Acetate Ophthalmic Suspension

Eligibility and Restrictions for Use

Who Can and Cannot Use Threolone?

Use of Threolone is governed by strict population-eligibility criteria defined in official regulatory documents.

Absolute Contraindications (Must NOT Use) Population/Condition Regulatory Status
Hypersensitivity Prohibited in individuals with known allergy to any component.
Blood Disorders Prohibited for patients with a personal or family history of aplastic anaemia or other blood dyscrasias.
Infections Prohibited in most cases of active viral, fungal, or mycobacterial infections at the site of use.
Ear Use Prohibited if the patient has a perforated eardrum (if used for ear conditions).

Special Population Restrictions While adults are generally eligible, use in certain groups requires caution or is not recommended. Children under two years require a prescription for use. The medicine is not recommended for women who are breastfeeding infants due to the potential for systemic exposure. Use during the last week of pregnancy should be avoided. Patients with pre-existing conditions like glaucoma or elevated intraocular pressure must use Threolone with caution and are subject to frequent monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Interaction Restrictions

The official regulatory profile for Threolone, a combination of Chloramphenicol and Prednisolone Acetate, outlines specific interaction constraints. Co-administration with medicines liable to depress bone marrow function must be avoided. This restriction is due to the potential for an additive, severe hematological risk associated with the Chloramphenicol component, as stipulated in official prescribing information.

Exposure Modification and Pharmacodynamic Effects

Pharmacokinetic interactions are formally documented, reflecting the systemic potential of the active ingredients. The Chloramphenicol component is known to potentially increase the systemic exposure (blood levels) of the co-active ingredient, Prednisolone, due to reduced clearance. Furthermore, caution is documented for co-administration with narrow therapeutic index drugs such as Phenytoin, as Chloramphenicol may increase their plasma concentration.

Topical Combination Risks

Interacting Substance Category Official Interaction Outcome
Medicines liable to depress bone marrow function Combination should be avoided (additive toxicity).
Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Increased potential for corneal healing problems (pharmacodynamic risk).

No mandatory timing separation rules or interactions with food, alcohol, or herbal products are explicitly documented in the official prescribing information for the topical product.

Mechanism of Action

How Threolone Works

Threolone functions as a highly specific, small-molecule modulator, targeting key components within cellular signaling systems. Its action is defined by engagement with two primary mechanistic domains: Receptor-Mediated Signaling Modulation and Pathway Feedback Regulation.

Threolone initiates or suppresses signaling sequences by engaging mechanisms that regulate specific receptor- or enzyme-mediated signaling. This interaction affects systems where specific neurotransmitters or mediators dominate, resulting in an altered profile of systemic physiological effects.

In parallel, the compound modifies early molecular steps within relevant intracellular cascades where multiple layers of pathway activation occur, influencing the establishment of specific pathway equilibria. Threolone’s action on feedback regulation within pathways participates in the attenuation of elevated physiological responses by modifying the kinetics of second messenger systems.

Dosage and Administration Information

How to Use Threolone: Official Administration Guidelines

Threolone, a combination of an antibiotic (Chloramphenicol) and a corticosteroid (Prednisolone Acetate), is officially designed for Topical Ocular administration as an ointment. The usage protocol defines the precise quantity, schedule, and duration of the course.


Administration Scope

Instruction Official Administration Rule
Route of administration Topical Ocular (applied to the eye).
Dosing schedule A 1-centimetre strip of ointment is applied to the conjunctival sac.
Frequency Typically three to four times daily, or as frequent as every three hours during waking hours in acute situations.
Course Duration The course is generally 5 days but must continue for at least 48 hours after symptoms clear. The maximum duration must not exceed 10 to 14 days.
Age-group Rules Elderly Adults typically require no dose adjustment. Use in newborn infants may necessitate dose modification due to systemic elimination capacity.

Procedural Structure

Official instructions require precise application: A small strip of the ointment is placed directly into the conjunctival sac of the affected eye, followed by gently closing the eye to ensure distribution. Crucially, the applicator tip must not touch the eye or any surrounding surfaces to preserve the product's sterility.


This protocol mandates the standardized approach for using the fixed-dose combination, establishing the required quantity, frequency, and duration for the short-term topical course.

Recent Clinical Evidence

Threolone: Overview of Studies

This overview summarizes the structure of clinical research for the combination of Chloramphenicol (antibiotic) and Prednisolone Acetate (glucocorticoid), focusing on study design, populations, and research gaps, without making claims of effectiveness.


Evidence for Use in Dermatoses Requiring Combined Anti-inflammatory and Antibacterial Action

Research explored the fixed-dose combination product in studies involving skin conditions characterized by fluctuating or episodic manifestations that involve both inflammation and a bacterial presence. The research conducted included short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. The studies monitored disease severity scores and outcomes related to physical discomfort (like redness and itching).

Findings were mixed when comparing the fixed combination against the individual components alone. Evidence is limited because the research relies substantially on studies involving similar drug combinations rather than this specific fixed-dose product. Follow-up durations were limited, meaning long-term effects are not fully established.


Evidence in Special Patient Populations and Research Gaps

Studies primarily focused on adult patient populations. Data for certain groups remain insufficient, including for children or older adults. Similarly, comparative evidence is lacking for patients with comorbid conditions or for the patterns observed in individuals who are pregnant.

Across the research landscape, evidence quality varies across studies, and follow-up durations were limited. The results apply only to the populations studied in the primary clinical trials, and research is ongoing to better contextualize how this medication fits into the broader evidence landscape.

Key Studies & References Topical Antibiotics for Infected Dermatitis: Summary of Findings of Included Systematic Reviews

Frequently Asked Questions (FAQ)

Common questions about Threolone (FAQ)

Q: How is Threolone different from other similar medications?

Official documents describe Threolone as a fixed-dose product that combines two different types of medicine: a broad-spectrum antibiotic (Chloramphenicol) and a potent glucocorticoid (Prednisolone Acetate).

This combination is officially designated for use in specific skin conditions that require both control of bacterial growth and reduction of severe inflammation.


Q: Can Threolone be taken with common pain relievers like ibuprofen?

The official safety information advises caution regarding other medicines. Specifically, using the ointment alongside topical non-steroidal anti-inflammatory drugs (NSAIDs) can increase the risk of corneal healing problems.

Regulatory documents do not contain explicit information documented for or against oral non-prescription pain relievers.


Q: What should I generally expect to feel when Threolone begins to work?

The therapeutic action of this combination product is intended to provide relief from discomforting symptoms such as swelling, redness, and itching.

Regulatory information notes it is common for patients to experience transient effects like a mild burning or stinging sensation, or local irritation at the site of application.


Q: Why is Threolone listed with a Black Box Warning on the FDA label?

The high-level regulatory warnings are due to rare but serious risks associated with the Chloramphenicol component.

The official safety profile documents the potential for severe hematological risks, such as aplastic anemia and bone marrow suppression. These serious risks are the basis for stringent regulatory labeling on products containing this ingredient.


Q: What warnings does the official patient information sheet give?

The official patient sheet provides several key warnings, including the need to maintain strict sterility during application and to keep the product out of reach of children.

Due to the severe burn risk from the ointment's flammable components transferring to fabrics, official patient documents state that users are instructed not to smoke or go near naked flames.


Q: Is Threolone considered a major drug interaction risk?

The regulatory profile highlights several significant drug interaction constraints. Official documents describe the need for caution with medicines that have a narrow therapeutic index (meaning small changes in dose can cause toxicity), such as Phenytoin.

Co-administration with medicines that depress bone marrow function must be avoided due to potential additive toxicity.


Q: How is Threolone classified by government drug agencies?

Regulatory agencies classify Threolone as a synthetic fixed-dose combination product containing a broad-spectrum antibiotic and a potent glucocorticoid (corticosteroid).

It is administered solely via the topical ointment route for localized action.


Q: What does 'contraindicated' mean in relation to Threolone?

In official drug documents, a contraindication is a condition or circumstance that makes the use of the medicine absolutely prohibited, as the risk of harm outweighs the potential benefit.

For this product, contraindications include a personal or family history of aplastic anaemia and the presence of most active viral or fungal infections at the site of use.


Q: What is the risk of allergic reaction to Threolone?

Official documents state that hypersensitivity (an allergic reaction) to any ingredient is an absolute contraindication, meaning use is strictly prohibited.

The specific symptoms or frequency of allergic reactions are not typically documented in general regulatory summaries for the topical product.


Q: Does Threolone cause weight gain or weight loss?

Systemic absorption of the corticosteroid component, Prednisolone, carries an associated risk profile. When used systemically, this component is commonly linked to side effects including increased appetite and weight gain.

Official documents acknowledge the risk of systemic absorption, especially with prolonged or widespread topical use.


Q: How long does it usually take for Threolone to start working?

Regulatory information regarding the antibiotic component suggests that patients generally start to see an improvement within 2 days of beginning treatment.

The duration of the full treatment course is short and is typically defined in official instructions as needing completion even after symptoms clear.


Q: Is it common to feel tired or dizzy while using Threolone?

Official documents for the active ingredients note a potential for systemic effects, including behavioral or mood changes associated with the corticosteroid component.

General systemic effects like tiredness or dizziness are not commonly listed for the topical formulation.


Q: How long does the effect of Threolone last in the body?

Pharmacokinetic data shows that the active ingredients have a relatively short duration in the body.

The half-life of the antibiotic component (Chloramphenicol) is generally 1.5 to 3.5 hours, and the corticosteroid (Prednisolone Acetate) half-life is typically 2 to 3 hours in adults with normal function.


Q: Does Threolone affect my ability to drive or operate machinery?

As the product is an ocular ointment, the application process may cause temporary blurred vision.

Official patient information for similar ophthalmic products describes that patients are advised to refrain from driving or operating machinery until any visual effects have fully cleared and their vision is stable.


Q: What are the known potential interactions with heart medications?

Regulatory documents describe the need for caution for co-administration with narrow therapeutic index drugs such as Phenytoin.

This is a medication that may be used to treat certain heart rhythm disorders or seizures, and its blood levels can be increased by the Chloramphenicol component.


Q: What happens if a person uses too much Threolone?

Overuse or prolonged application of the corticosteroid component can increase the risk of serious systemic effects, such as HPA axis suppression (a problem with the body's hormone regulation).

Additionally, high systemic exposure to the antibiotic component in newborns is associated with the risk of gray baby syndrome.


Q: Does Threolone have an effect on mood or sleep patterns?

Official documents for the active ingredients note an association with behavioral and mood changes for the corticosteroid component when systemically absorbed.

Furthermore, the antibiotic component has been associated with some reports of effects such as mild depression and hallucinations.


Q: Why do some people need to be tested before starting Threolone?

The medicine is absolutely prohibited for individuals with a personal or family history of aplastic anaemia or other blood disorders.

Due to this severe, documented risk, regulatory information indicates that certain patients are subject to careful assessment of their medical history or blood counts before and during treatment.


Q: Can Threolone affect blood pressure levels?

The corticosteroid component is associated with potential side effects including elevation in blood pressure when used systemically.

Official documents acknowledge the risk of systemic absorption with topical application, especially with prolonged or high-dose use.

How should Threolone be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation defines strict mandates for the storage, handling, and disposal of Threolone (Chloramphenicol, Prednisolone Acetate) Ointment.

Requirement Area Official Mandate
Temperature and Light Must be stored below 25 C and in a dark place in a tightly closed container.
Product Stability Prohibited from use after the expiry date appearing on the package.
Child Safety Must be kept out of the reach and sight of children and/or infants to avoid poisoning.
Special Handling Patients are instructed not to smoke or go near naked flames due to a severe burn risk from the ointment's flammable components transferring to fabric.
Disposal Do not discard in wastewater or domestic trash; the product must be disposed of by asking a pharmacist or following local pharmaceutical waste regulations.

The official labeling specifies these environmental controls and safety constraints to maintain product integrity and prevent harm. These requirements must be followed exactly as stated in the product's regulatory documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Threolone found in:

A-Z Index: